sodium iodide [131i] diagnostic capsules ge healthcare 3.7 mbq
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard - 3.7 mbq
thallous (201ti) chloride 37 mbq/ ml
curium netherlands b.v. - talliumklorid (201tl) - injeksjonsvæske, oppløsning - 37 mbq/ ml
technescan dmsa 1.2 mg
curium netherlands b.v. - dimerkaptosuccininsyre - preparasjonssett til radioaktive legemidler - 1.2 mg
nanocis 0.15 mg
cis bio international - rheniumsulfid - injeksjonsvæske, oppløsning - 0.15 mg
tecfidera 240 mg
2care4 aps - dimetylfumarat - enterokapsel, hard - 240 mg
tecfidera 240 mg
orifarm as - dimetylfumarat - enterokapsel, hard - 240 mg
tecfidera 120 mg
orifarm as - dimetylfumarat - enterokapsel, hard - 120 mg
pantoprazol oresund pharma 40 mg
oresund pharma aps - pantoprazolnatriumsesquihydrat - pulver til injeksjonsvæske, oppløsning - 40 mg
somac 40 mg
orifarm as - pantoprazolnatriumsesquihydrat - pulver til injeksjonsvæske, oppløsning - 40 mg
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressive - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.